Phase II study of alanine mustard (NSC-17663).
D000409:Alanine / Q000627:therapeutic use* / Q000633:toxicity; D001772:Blood Cell Count; D001853:Bone Marrow / Q000187:drug effects; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy* / Q000401:mortality; D009150:Mustard Compounds / Q000627:therapeutic use* / Q000633:toxicity; D009325:Nausea / Q000139:chemically induced; D013924:Thrombophlebitis / Q000139:chemically induced
D009150:Mustard Compounds; D000409:Alanine